financetom
Business
financetom
/
Business
/
Calumet Closes $1.44 Billion DOE Loan to Expand Montana Renewables' Fuel Facility
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Calumet Closes $1.44 Billion DOE Loan to Expand Montana Renewables' Fuel Facility
Jan 10, 2025 2:30 PM

05:01 PM EST, 01/10/2025 (MT Newswires) -- Calumet (CLMT) said Friday it closed a $1.44 billion guaranteed loan facility with the US Department of Energy to back the construction and expansion of the renewable fuels facility owned by its subsidiary, Montana Renewables.

The expansion project is set to position Montana Renewables as one of the largest sustainable aviation fuel producers globally, increasing annual production capacity to about 300 million gallons of SAF, according to the company.

The company said that the first tranche of $782 million will fund previously incurred eligible expenses, with additional funds disbursed during construction through 2028.

Calumet shares were rising nearly 8% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
U.S. Global Investors Q1 net income jumps 378% helped by investment income gains
U.S. Global Investors Q1 net income jumps 378% helped by investment income gains
Nov 12, 2025
Overview * U.S. Global Investors ( GROW ) fiscal Q1 net income rises 378% yr/yr, driven by investment income * Company fiscal Q1 operating revenues up 15% from June qtr, 4% yr/yr * Fund flows into gold mining and natural resource funds turn positive Result Drivers * INVESTMENT INCOME - Net income increase largely driven by investment income, which rose...
Cue Biopharma Q3 collaboration revenue falls
Cue Biopharma Q3 collaboration revenue falls
Nov 12, 2025
Overview * Cue Biopharma ( CUE ) Q3 collaboration revenue declines * Company announces $15 mln collaboration with ImmunoScape for cell therapy development * Operating expenses decreased due to lower clinical trial costs and compensation Outlook * Company did not provide specific financial guidance for future quarters in its press release Result Drivers * REDUCED R&D EXPENSES - Decrease in...
Lyell Immunopharma Q3 adjusted net loss beats estimates
Lyell Immunopharma Q3 adjusted net loss beats estimates
Nov 12, 2025
Overview * Lyell Q3 adjusted net loss beats analyst expectations * Company acquired global rights to LYL273, a GCC-targeted CAR T-cell product * Initiated PiNACLE - H2H Phase 3 trial for aggressive large B-cell lymphoma Outlook * Company expects to begin PiNACLE - H2H trial enrollment by early 2026 * Lyell anticipates LYL273 Phase 1 trial data update in H1...
Shah Capital pushes for Novavax sale, warns of proxy fight
Shah Capital pushes for Novavax sale, warns of proxy fight
Nov 12, 2025
* Shah Capital frustrated with Novavax's ( NVAX ) weak COVID-19 vaccine sales * Hedge fund increases stake to 8.3%, urges sale to large pharma * Novavax's ( NVAX ) COVID vaccine sales lag behind competitors By Sneha S K and Sriparna Roy Nov 12 (Reuters) - Shah Capital, Novavax's ( NVAX ) second-largest shareholder, is pressing the biotech's board...
Copyright 2023-2026 - www.financetom.com All Rights Reserved